Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (241-250 of 706) with videos related to

Pageof 71
Sort By:
Clinical Cardiology|July 11, 2017
Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding eventsGilles Lemesle, Gregory Ducrocq, Yedid Elbez, et al.
Journal of the American College of Cardiology|October 2, 2002
Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromesNeal S Kleiman, Nasser Lakkis, Christopher P Cannon, et al.
Clinical Cardiology|December 25, 2018
Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registryJohanna P Contreras, Kimberly N Hong, Javier Castillo, et al.
American Heart Journal|April 29, 2008
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor useMarc S Sabatine, Hussam N Hamdalla, Shamir R Mehta, et al.
International Journal of Cardiology|January 12, 2008
The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromesShaheeda Ahmed, Christopher P Cannon, Robert P Giugliano, et al.
International Journal of Cardiology|December 19, 2024
Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registryBenjamin E Peterson, Deepak L Bhatt, Christie M Ballantyne, et al.
Coronary Artery Disease|October 15, 2016
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemiaJohn J P Kastelein, Dean J Kereiakes, Christopher P Cannon, et al.
Critical Pathways in Cardiology|March 11, 2010
Regional differences in quality of care and outcomes for the treatment of acute coronary syndromes: an analysis from the get with the guidelines coronary artery disease programWarren Laskey, Nathan Spence, Xin Zhao, et al.
American Heart Journal|October 18, 2008
Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular diseaseBenjamin A Steinberg, Deepak L Bhatt, Shamir Mehta, et al.
Lancet (London, England)|November 13, 2020
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trialsBaris Gencer, Nicholas A Marston, KyungAh Im, et al.
Pageof 71

Showing results (241-250 of 706) with videos related to

Sort By:
Pageof 71
Clinical Cardiology|July 11, 2017
Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding eventsGilles Lemesle, Gregory Ducrocq, Yedid Elbez, et al.
Journal of the American College of Cardiology|October 2, 2002
Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromesNeal S Kleiman, Nasser Lakkis, Christopher P Cannon, et al.
Clinical Cardiology|December 25, 2018
Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registryJohanna P Contreras, Kimberly N Hong, Javier Castillo, et al.
American Heart Journal|April 29, 2008
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor useMarc S Sabatine, Hussam N Hamdalla, Shamir R Mehta, et al.
International Journal of Cardiology|January 12, 2008
The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromesShaheeda Ahmed, Christopher P Cannon, Robert P Giugliano, et al.
International Journal of Cardiology|December 19, 2024
Inadequate Intensification of LDL-cholesterol lowering therapy after coronary revascularization: Insights from the GOULD registryBenjamin E Peterson, Deepak L Bhatt, Christie M Ballantyne, et al.
Coronary Artery Disease|October 15, 2016
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemiaJohn J P Kastelein, Dean J Kereiakes, Christopher P Cannon, et al.
Critical Pathways in Cardiology|March 11, 2010
Regional differences in quality of care and outcomes for the treatment of acute coronary syndromes: an analysis from the get with the guidelines coronary artery disease programWarren Laskey, Nathan Spence, Xin Zhao, et al.
American Heart Journal|October 18, 2008
Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular diseaseBenjamin A Steinberg, Deepak L Bhatt, Shamir Mehta, et al.
Lancet (London, England)|November 13, 2020
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trialsBaris Gencer, Nicholas A Marston, KyungAh Im, et al.
Pageof 71